The week in industry: Bid to outlaw off-label Avastin use rejected by UK High Court
Read our round-up of some of the breaking news from the pharmaceutical industry over the past week. This week: Novartis to cut over 2000 jobs between Switzerland and the UK and Gilead has announced plans to launch generic versions of its leading hepatitis C therapies.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>